Renal Cancer - Results from #2000

Folate-targeted intraoperative fluorescence, OTL38, in robotic-assisted laparoscopic partial nephrectomy. June 11, 2021

Optimal Surgical Outcome of Minimally Invasive Partial Nephrectomy (MIPN) Based on an Early Postoperative Estimated Glomerular Filtration Rate (eGFR). June 10, 2021

Prognostic Role of the Ubiquitin Proteasome System in Clear Cell Renal Cell Carcinoma: A Bioinformatic Perspective. June 9, 2021

A contemporary guide to chromosomal copy number profiling in the diagnosis of renal cell carcinoma. June 9, 2021

Prognostic significance of the controlling nutritional status score in patients with metastatic renal cell carcinoma diagnosed before an era of first-line immune-oncology combination therapies. June 8, 2021

The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care. June 8, 2021

Salvage Robot-assisted Renal Surgery for Local Recurrence After Surgical Resection or Renal Mass Ablation: Classification, Techniques, and Clinical Outcomes. June 7, 2021

Sunitinib and Axitinib increase secretion and glycolytic activity of small extracellular vesicles in renal cell carcinoma. June 7, 2021

Exelixis Announces Positive Phase 2 Results for cabozantinib in Combination with nivolumab in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma at ASCO 2021 June 4, 2021

Prognostic Role of Circulating Tumor Cells (CTCS) in Metastatic Renal Cell Carcinoma: A Large, Multicenter Prospective Trial. June 4, 2021

Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma: A Concluded Living Systematic Review and Meta-Analysis. June 4, 2021

Intermediate- and long-term oncological outcomes of active surveillance for localized renal masses: a systematic review and quantitative analysis. June 3, 2021

Differences in risk factors for molecular subtypes of clear cell renal cell carcinoma. June 3, 2021

Metastasis-directed stereotactic body radiotherapy for oligometastatic renal cell carcinoma: extent of tumor burden eradicated by radiotherapy. June 2, 2021

High response rate and durability driven by HLA genetic diversity in kidney cancer patients treated with the immunotherapy combination lenvatinib and pembrolizumab. June 2, 2021

American Urological Association (AUA) Announces Updates to Clinical Guidance for Renal Mass and Localized Renal Cancer June 1, 2021

Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). June 1, 2021

Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell Carcinoma. June 1, 2021

Retroperitoneal versus transepritoneal robot-assisted partial nephrectomy for postero-lateral renal masses: an international multicenter analysis. May 31, 2021

Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma. May 31, 2021

Page 101 of 456